RESUMO
Clostridium difficile-associated pseudomembranous colitis (PMC) is a common affliction of postoperative patients. Risk factors include antibiotic therapy, recent surgery, and hospitalization (1,2,3). We present a case of PMC in a diverted colon and its treatment using vancomycin enemas.
Assuntos
Antibacterianos/administração & dosagem , Clostridioides difficile , Infecções por Clostridium/tratamento farmacológico , Divertículo do Colo/complicações , Enterocolite Pseudomembranosa/tratamento farmacológico , Vancomicina/administração & dosagem , Infecções por Clostridium/complicações , Enema , Enterocolite Pseudomembranosa/complicações , Enterocolite Pseudomembranosa/microbiologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Vaccinia melanoma oncolysate is an investigative agent for active specific adjuvant immunotherapy. Viral oncolysate work in animals has led to application of this treatment in humans. Success of initial trials in treatment of melanoma has led to a phase III randomized, prospective, double-blind, multi-institutional trial, which is currently under way.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Antígenos de Neoplasias/uso terapêutico , Antígenos Virais/uso terapêutico , Imunoterapia Ativa/normas , Melanoma/terapia , Neoplasias Cutâneas/terapia , Vaccinia virus/imunologia , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/farmacologia , Animais , Membrana Celular/imunologia , Avaliação Pré-Clínica de Medicamentos , Humanos , Imunoterapia Ativa/métodos , Melanoma/imunologia , Melanoma/mortalidade , Ensaios Clínicos Controlados Aleatórios como Assunto , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/mortalidade , Taxa de SobrevidaRESUMO
Conventional treatment of cancer, especially for patients with metastatic melanoma tumor, is often ineffective. Immunotherapy and recently introduced gene therapy have revolutionized the treatments of patients with metastatic melanoma tumor. Use of biological response modifiers, such as interleukins and interferons, have been found to enhance therapeutic benefits to patients with malignant melanoma. Initial studies with a high-dose interleukin-2 (IL-2) therapy have proved effective in patients with melanoma tumor, although a variety of systemic toxicities were observed. A low-dose IL-2 continuous infusion has shown a similar response in patients with melanoma tumor, but produced lesser toxicity. The low-dose IL-2 therapy has been studied with an adoptive transfer combined with either autologous lymphokine activated killer cells or autologous tumor infiltrating lymphocytes (TIL). IL-2 in combination with chemotherapeutic agents such as flavone acetic acid, dacarbazine, and cyclophosphamide have also been studied in patients with metastatic melanoma. Results have shown a moderate response in patients with metastatic melanoma. TIL therapy, however, has been shown to result in higher objective regression due to potent tumor-specific killing and tumor-specific targeting characters of the TIL. The tumor targeting nature of the TIL creates the possibility of using TIL as a vehicle to deliver gene product specifically to tumor tissue. Safety and toxicity of gene-transduced TIL were addressed by the use of neomycin-resistant, gene-transduced TIL in patients with metastatic melanoma. We also investigated the use of vaccinia oncolysate therapy by using the viral oncolysate prepared with IL-2 gene encoded vaccinia virus. Preliminary studies with murine hepatic metastases colon model have shown encouraging results.
Assuntos
Terapia Genética/normas , Linfocinas/uso terapêutico , Melanoma/terapia , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/uso terapêutico , Ensaios Clínicos como Assunto , Terapia Combinada , Avaliação de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Terapia Genética/métodos , Humanos , Imunoterapia Adotiva/métodos , Imunoterapia Adotiva/normas , Interleucina-2/administração & dosagem , Interleucina-2/uso terapêutico , Células Matadoras Ativadas por Linfocina/imunologia , Linfócitos do Interstício Tumoral/imunologia , Linfocinas/administração & dosagem , Linfocinas/imunologia , Melanoma/genética , Melanoma/secundário , Vaccinia virus/imunologiaRESUMO
A patient with multiple pyogenic abscesses in both lobes of the liver secondary to asymptomatic sigmoid diverticulitis is presented. The rarity of this illness is noted. It is suggested that barium enema be performed in patients who present with pyogenic liver abscess of unknown etiology because of the association with asymptomatic sigmoid diverticulitis.